Tuesday, August 4, 2015

Aristocrat Group Corp. (ASCC) Positioned to Capitalize on Consumer Premium Spirit Popularity

Bolstering the Aristocrat Group’s focus on expanding distribution of its RWB Ultra-Premium Handcrafted Vodka, the company reports that an industry leader recently confirmed an encouraging trend: Americans are increasingly opting for premium spirits.

CEO Ivan Menezes of Diageo, the maker of top brands such as Smirnoff and Ciroc, last week told CNBC that American consumers are “drinking better” and trending toward top-shelf premium spirits in the current age of craft cocktails – confirming ASCC’s research that premium spirits are taking an industry lead.

ASCC CEO Robert Federowicz says that RWB Vodka strongly positions the company to capitalize on the wave of interest in top-quality spirits.

“RWB Vodka is one of the most highly decorated American spirits in the marketplace,” he stated in the news release. “Our sales and distribution will keep growing as word of mouth continues to spread about RWB’s premium flavor and smooth finish.”

ASCC’s handcrafted, American-made RWB Ultra-Premium Handcrafted Vodka is made with the highest-quality Idaho potatoes and pure mountain spring water and then refined by a five-stage filtration system that produces gluten-free, high-class vodka. It is available online to U.S. consumers and at many retail locations, clubs, bars and restaurants.

For more information visit www.aristocratgroupcorp.com/investors or www.rwbvodka.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

On the Move Systems, Inc. (OMVS): Shared Economy Services Drive Job Creation, Growth

On the Move Systems, currently exploring new online tools to reduce costs and increase convenience in the tourism and travel industry and exploring new opportunities in trucking, in recent weeks has issued a number of news releases publicizing market potential for the company’s proposed online, on-demand courier service.

The company this morning pointed out that the shared economy, similar to the business model used at Uber, is beneficial for people looking for “steady, flexible employment or extra income” as a means to profit from the increasingly popular business model. As such, OMVS says it is considering workforce potential as it continues to scout possible locations for courier service.

“We are looking for a location that has an ample workforce, and one that is open to a flexible arrangement,” OMVS CEO Robert Wilson stated in the news release. “An online, on-demand courier service is not a typical 9-5 job. It requires not only rapid mobility, but quick adaptability as well, as the business needs are constantly changing. Right now, urban areas with young populations, particularly college students or recent graduates, appear quite promising, as people in this group always need extra income, can be highly flexible in terms of time and are open to new ways of doing business.”

OMVS also notes research showing that the Millennial generation considers the shared economy to be “hip and cool” – this generation is quickly adapting not only to using shared economy services, but increasingly becoming an active participant in them.

“Younger consumers and workers embrace technology and are willing to share – key components for success in any shared economy venture,” states the company.

A recent survey revealed nearly three out of four Americans might utilize such a service within the next two years.

For more information, visit www.onthemovesystems.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

Monday, August 3, 2015

International Stem Cell Corp. (ISCO) Parkinson’s Treatment Just the Tip of the Iceberg for Stem Cell Technology Platform

The fact that novel stem cell therapy developer, International Stem Cell (OTCQB: ISCO), is now rapidly advancing from highly successful preclinical studies in Parkinson’s Disease (PD) using human parthenogenetic neural stem cells (hpNSC) derived from its proprietary stem cell technology platform toward a landmark phase 1/2a clinical study clinical study in Australia, has sparked renewed interest in the investment community regarding the company’s technology. After the publication of data on two proof of concept PD studies, demonstrating the safety and functional efficacy of the company’s human parthenogenetic stem cells (hpSCs) – an entirely new class of stem cells created using unfertilized eggs which substantially addresses the problem of cell transplant immune-rejection – the fundamental viability of ISCO’s hpSC approach and the potential for the upcoming clinical trial in PD have caused many in the investment community to dig deeper into ISCO’s dynamic platform.

Given the recent projection by research and consulting firm GlobalData that the PD treatment market alone will continue to grow alongside an ageing global population, running a CAGR of around four percent over the next several years, before hitting around $5.3 billion in 2022, the development of a viable treatment option by ISCO could be a major victory for the company and for patients; a victory which would also broadly legitimize the company’s existing clinical pipeline, while adding fuel to the fire of its existing commercialization. It is important to note that when it comes to PD, leading dopamine agonists like pramipexole and ropinirole, or Neupro/Leganto (rotigotine), work by merely imitating dopamine, stimulating the brain in a similar fashion and thus making up for the dopamine-producing cells that have died due to the onset of PD.

Dopamine agonist regimens do not represent a real treatment and merely mask the underlying disease. While such PD regimens return some percentage of motor and cognitive control to the patient, they are a far cry from the demonstrated ability of ISCO’s transplanted hpNSCs to both actively differentiate into new dopamine-producing neurons and simultaneously act as a neuroprotectant, addressing both the patient’s current symptoms and helping to stop further deterioration. ISCO’s approach is closer to that of regenerative medicine company Neuralstem, Inc. (NYSE: CUR), whose initial therapeutic product, derived from spinal cord neural stem cell lines, has received FDA orphan status for application in ALS, more commonly known as Lou Gehrig’s disease.

In ISCO’s case, the derivation and implementation methodologies are of particular interest, especially given the immune-matching aspects of the technology and its scalability potential, both in terms of producing large quantities of stem cells for transplant and with regard-  to addressing therapeutic avenues beyond the scope of the company’s current clinical pipeline. As the company moves out of the preclinical stage in its work on PD using hpNSCs, which have also shown significant promise as a legitimate treatment option for actually reversing the functional deficits associated with a stroke, when administered even weeks after the actual event, it makes sense to take a look at ISCO’s already functional commercial operations based on its stem cell platform technology. This is especially true given the company’s ongoing work with hpSC-derived human retinal epithelium (RPE) cells for treating retinal and corneal blindness, as well as its stem cell-derived liver cell (CytoHep) program, which is focused on developing metabolic liver disease therapies.

A solid five percent sales uptick for Q1 this year compared to 2014 reported by the company’s Lifeline Skin Care subsidiary – which leverages the same ethically-derived stem cell platform technology to create an extract for use in skin care products that have demonstrably shown an ability to improve elasticity, firmness, tone and other sought-after qualities – is a solid indicator of the company’s existing ability to generate revenue from its technology, even before commercialization of the clinical pipeline has been realized. With the global facial skin care market on track to hit somewhere in the neighborhood of $40 billion by 2019 (Transparency Market Research), driven in part by the fact that more and more men are beginning to show an increased awareness of and concern for their skin’s health, ISCO’s capacity to bring revolutionary products to market based on far more potent non-embryonic stem cells than the adult stem cells used by many other entrants to this burgeoning segment of the skin care market, has already placed the company in a class all its own.

A full lineup of facial skin care products, including an antioxidant polisher, brightening cleanser and exfoliating preparation, roundly back up Lifeline Skin Care’s eye firming complex and revitalizing moisture serum products, which are made possible by a nanotech encapsulation of the stem cell extract’s key proteins. This unique encapsulation of the proteins in an oily two-layer sphere, allows Lifeline products to penetrate deep into the middle layer of the skin, the dermis, where collagen and elastin (the main structural and elastic peptides that give the skin its youthful qualities) are produced.

Lifeline Skin Care customers rave about the results, expressing most often how much lighter and brighter their skin looks and feels. Given the continued success of the company’s clinical pipeline and the demonstrable efficacy of hpSCs in treating notoriously difficult CNS conditions like PD, it is not hard to understand why Lifeline Skin Care products have become so beloved by consumers. The idea of actually replacing skin proteins with high-potency, nanotech encapsulated, small-molecule and therefore readily absorbed proteins is a significant technological leap beyond what other stem cell-based skin care companies have been doing. Clinical laboratory studies showing a 46 percent increase in elastin, and a 48.5 percent on average increase for the two primary types of collagen when using Lifeline stem cell products, adds readily quantifiable weight to the documented expressions by consumers about how their skin feels brighter, more luminous, and healthier after using the products.

Operating income for ISCO from both aforementioned cosmeceutical commercialization and the company’s ongoing biomedical commercialization, which is executed under the company’s Lifeline Cell Technology subsidiary, was up some 76 percent in Q1 this year compared to 2014. Lifeline Cell Technology has quickly become an industry leader in supplying purified primary human cells and optimized cell culture reagents, and while this market is not as immediately lucrative as skin care, the long-term revenue generation potential as the stem cell industry evolves is considerable in its own right. With the best Q1 financial performance owing to the company’s cosmeceutical division, investors should take note of ISCO’s ability to generate revenues well before its clinical pipeline achieves commercialization, a feat of which very few young biotechs can boast.

Cancer is another huge area where we could see such technology revolutionize the way therapy is handled. Stem-cell transplantation following high-dose chemotherapy for instance, has emerged as an established treatment modality for a variety of hematologic malignancies, such as leukemia, lymphoma, and multiple myeloma. The company’s capacity to produce large volumes of immune-matched stem cells using its proprietary parthenogenetic derivation technology, at its GMP facility in Oceanside, California, is a key strategic and logistical advantage here as well. Even such innovators like clinical-stage biopharma BioLineRx (NASDAQ: BLRX) – which recently announced robust stem-cell mobilization capability with its lead oncology candidate, allowing for harvesting of enough cells needed to transplant from healthy volunteers into patients with hematological malignancies – are notably handicapped by comparison when it comes to cell source logistics.

Learn more about the company by visiting www.internationalstemcell.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

WellQuest Medical & Wellness Corp. (WEQL) Integrating Physician Healthcare with Wellness Services in Innovative Medical Facilities

WellQuest Medical & Wellness Corp. offers innovative healthcare delivery options by integrating conventional and complementary physician medicine with specially-designed wellness services, creating a more effective environment for the pursuit and maintenance of a healthy lifestyle. The company currently operates two peaceful and beautiful facilities in Bentonville, Arkansas, and Tulsa, Oklahoma, which offer a collection of treatment options targeted at the unique needs of its clients – including a full range of both traditional medical services and lifestyle-based programs.

In recent years, the market for health and wellness solutions has experienced steady growth. In 2014, the industry accounted for approximately $16 billion in revenue, and additional growth is forecast at an annualized rate of 4.2 percent through 2020, according to IBISWorld. When combined with the performance of the massive national healthcare industry, which accounted for more than $1.6 trillion in revenue in 2014, according to the U.S. Census Bureau, it becomes apparent that the market potential of WellQuest’s unique approach to healthcare is immense.

Since opening its first expansion site in late 2013, WellQuest has successfully leveraged the marketability of its innovate healthcare facilities to record strong financial growth. In its fiscal year 2014, the company recorded a 25 percent increase in annual revenue, as compared to the previous year. Additionally, the company realized a 27 percent rise in gross profit for the period. WellQuest built on this performance in the first quarter of 2015, recording a mild quarter-over-quarter improvement in total revenue.

Moving forward, WellQuest will look to capitalize on the recent changes to the healthcare marketplace, which the company suggests have created higher demand for primary care medicine, fresh wellness initiatives, corporate wellness programs and integration of medical treatment and lifestyle wellness. Look for WellQuest to make additional progress toward its goal of opening additional locations across the country in the years to come, providing a platform upon which it could greatly increase its national market share while promoting sustainable investor returns.

For more information, visit www.wellquestmedical.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

Latitude 360, Inc. (LATX) Engages QualityStocks Investor Relations Services

Latitude 360, an award-winning pioneer of combining premier upscale casual dining with state-of-the-art entertainment, today announces that it has engaged the investor relations services of QualityStocks. Based in Scottsdale, Arizona, QualityStocks has assisted more than 300 public companies with their efforts to broaden influence, attract growth capital and improve shareholder value.

“The Latitude 360 brand is rapidly growing in the food and entertainment industry, and with our recent partnership and pending acquisition of Major League Fantasy, we’ve also made a sizeable entrance into the multi-billion dollar sports fantasy market,” stated Latitude 360 CEO Brent Brown. “As we continue to expand our portfolio, explore options to grow our brick and mortar locations, and fine-tune our strategy in fantasy sports, QualityStocks will work on communicating our performance to potential shareholders. For existing shareholders, this partnership represents our commitment to clear and concise communication through this exciting season of growth.”

QualityStocks will use its network of partners, daily and weekly newsletters, social media channels, blog and other outreach tools to raise visibility of Latitude 360 among current shareholders as well as the larger investment community.

“Latitude 360 employs a unique business model that, when combined with exemplary management, positions the company on trek for incredible growth,” stated QualityStocks Managing Director Michael McCarthy. “As a trusted partner, the QualityStocks team will apply a vast network of resources, tools and experience to elevate the Latitude 360 brand and communicate the company’s progress and achievements to the broader market.”

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

Loans4Less.com, Inc. (LFLS) Sharpens Focus on Launch of National Mortgage Broker Channel following Expiration of Planned 321Lend Acquisition

In March, Loans4Less.com, Inc. entered into an acquisition agreement with 321Lend, Inc. that was expected to make the fully-integrated consumer lending and peer-to-peer technology platform a wholly-owned subsidiary of Loans4Less. However, on Saturday, the company issued a statement announcing that it will no longer be pursuing the acquisition following the expiration of the original agreement on July 31, 2015.

Following this development, Loans4Less will once again turn its attention toward its primary operational objective: entering into a strategic alliance with a community bank to launch a national mortgage broker retail channel for conforming home loans. In the coming months, the company expects to initiate a partnership with a suitable banking partner prior to beginning efforts to raise necessary capital. Upon completion of these milestones, Loans4Less intends to become a fully reporting company, enabling it to uplist to the OTCQB Venture Marketplace.

In December, the company took a noteworthy step toward meeting its ambitious strategic goals through the execution of an investment banking agreement with WestPark Capital, Inc. In addition to providing guidance in Loans4Less’s search for a community bank partner, WestPark is expected to play a significant role in increasing the company’s brand awareness and raising working capital in the future.

By successfully launching its national mortgage broker channel, Loans4Less will be in a formidable position to capitalize on the recent performance of the national mortgage industry. According to a report by the Mortgage Bankers Association, mortgage origination volume increased by nearly 33 percent in the second quarter of 2015, as compared to the same period in the previous year. In total, approximately $395 billion of mortgages were originated during the quarter. For Loans4Less, this strong industry growth could foreshadow an opportunity to dramatically expand its national market share following the location of an appropriate community partner.

For more information, visit www.Loans4Less.com

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.


Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net

Friday, July 31, 2015

Cherubim Interests, Inc. (CHIT) is “One to Watch”

Cherubim Interests is a development-stage alternative construction and real estate development company seeking various opportunities relative to the company’s management team of experts in property management, construction and finance.

The company’s primary focus is within the real estate development and controlled environment agriculture sectors, which Cherubim recently entered into by acquiring an exclusive worldwide license for the deployment of a proprietary plant cultivation technology. Through its wholly owned subsidiary, BudCube Cultivation Systems USA, Cherubim plans to construct, deploy and lease scalable medical and recreational marijuana cultivation facilities for commercial applications.

Coupled with a real estate development and property management business model, BudCube Cultivation Systems (“BCS”) can position itself anywhere in the world where the cultivation of cannabis is legal. BCS’s unique business model positions the company to greatly benefit as more market participants seek to gain entry into a fast-growing market at an attractive price point.

Armed with the ability to lease a portable and scalable turn-key cultivation solution to growers, Cherubim aims to use its licensed solution to fill the gap for both first-time and experienced cultivators who may not have the capital resources to buy land, construct or tenant-improve existing structures for the optimum environment for developing a high-quality cannabis product.

About QualityStocks

QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. We offer several ways for investors to find, evaluate, and learn more about investing in these companies.

Sign up for “The QualityStocks Daily Newsletter” at www.QualityStocks.net

The Quality Stocks Daily Blog http://blog.qualitystocks.net

The Quality Stocks Daily Videos http://videocharts.qualitystocks.net

 The Quality Stocks “Ones to Watch” http://gotstocks.qualitystocks.net

Please see disclaimer on the QualityStocks website: http://disclaimer.qualitystocks.net